Skip to main content
. 2024 Dec 5;11:2413–2425. doi: 10.2147/JHC.S483014

Table 1.

Baseline Patient Characteristics Between Laparoscopic Anatomical Liver Resection (LAR) and Laparoscopic Non-Anatomical Liver Resection (LNAR) Groups Before and After Propensity Score Matching (PSM)

Characteristics Before PSM After PSM
LAR (N=304) LNAR (N=357) P LAR (N=250) LNAR (N=250) P
Age 52.70±11.15 51.08±11.37 0.067 52.09±11.07 52.28±11.39 0.855
Gender 0.082 0.797
 Male 252 (82.9%) 313 (87.7%) 214 (85.6%) 216 (86.4%)
 Female 52 (17.1%) 44 (12.3%) 36 (14.4%) 34 (13.6%)
HBV 259 (85.2%) 309 (86.6%) 0.617 218 (87.2%) 212 (84.8%) 0.439
HCV 6 (2.0%) 2 (0.6%) 0.098 0 (0%) 2 (0.8%) 0.156
Liver cirrhosis 196 (64.5%) 238 (66.7%) 0.554 167 (66.8%) 162 (64.8%) 0.637
Child-Pugh score 1.000 1.000
 A 304 (100%) 357 (100%) 250 (100%) 250 (100%)
 B 0 (0%) 0 (0%) 0 (0%) 0 (0%)
ASA score 0.650 0.471
 I 168 (55.3%) 191 (53.5%) 143 (57.2%) 135 (54.0%)
 II 136 (44.7%) 166 (46.5%) 107 (42.8%) 115 (46.0%)
TBIL (µmol/L) 15.70±6.02 16.16±6.14 0.331 15.52±6.12 15.99±6.16 0.389
ALT (IU/L) 38.21±23.89 43.52±33.93 0.022* 39.56±24.91 38.21±26.33 0.556
ALB 42.15±4.06 42.68±3.97 0.093 42.45±3.96 42.43±3.98 0.952
PT (INR) 1.01±0.06 1.02±0.08 0.119 1.01±0.06 1.01±0.07 0.756
Plt (×103/μL) 150.27±69.52 130.11±54.46 <0.001* 138.68±55.73 140.20±58.47 0.767
ICG-R15 (%) 4.68±2.94 5.24±3.06 0.017* 4.75±2.94 4.68±2.73 0.777
AFP (≥400 ng/mL) 78 (25.7%) 99 (27.7%) 0.549 66 (26.4%) 63 (25.2%) 0.759
Largest tumor diameter 0.001* 0.647
 ≤ 5cm 225 (74.0%) 303 (84.9%) 201 (80.4%) 205 (82.0%)
 >5cm 79 (26.0%) 54 (15.1%) 49 (19.6%) 45 (18.0%)
Tumor number 0.016* 0.112
 1 292 (96.1%) 324 (90.8%) 241 (96.4%) 236 (94.4%)
 2–3 10 (3.3%) 31 (8.7%) 7 (2.8%) 14 (5.6%)
 ≥4 2 (0.7%) 2 (0.6%) 2 (0.8%) 0 (0%)
Range of LR 0.078 0.455
 Minor 245 (80.6%) 306 (85.7%) 215 (86.0%) 209 (83.6%)
 Major 59 (19.4%) 51 (14.4%) 35 (14.0%) 41 (16.4%)
Tumor Location 0.024* 0.845
 Central segments (1, 4a, 7, 8) 80 (26.3%) 123 (34.5%) 73 (29.2%) 75 (30.0%)
 Peripheral segments (2, 3, 4b, 5, 6) 224 (73.7%) 234 (65.5%) 177 (70.8%) 175 (70.0%)
Resection tumor margin 0.306 0.432
 ≥1cm 290 (95.4%) 346 (96.9%) 241 (96.4%) 244 (97.6%)
 <1cm 14 (4.6%) 11 (3.1%) 9 (3.6%) 6 (2.4%)
Margin status 0.356 1.000
 Negative 304 (100%) 356 (99.7%) 250 (100%) 250 (100%)
 Positive 0 (0%) 1 (0.3%) 0 (0%) 0 (0%)
Histological grade 0.514 0.788
 Low 41 (13.5%) 39 (10.9%) 33 (13.2%) 30 (12.0%)
 Moderate 238 (78.3%) 292 (81.8%) 197 (78.8%) 203 (81.2%)
 High 25 (8.2%) 26 (7.3%) 20 (8.0%) 17 (6.8%)
Satellite nodule 0.064 1.000
 Positive 0 (0%) 4 (1.1%) 0 (0%) 0 (0%)
 Negative 304 (100%) 353 (98.9%) 250 (100%) 250 (100%)
TNM stage 0.041* 0.476
 I–II 301 (99.0%) 345 (96.6%) 247 (98.8%) 245 (98.0%)
 III–IV 3 (1.0%) 12 (3.4%) 3 (1.2%) 5 (2.0%)

Note: *, P < 0.05, statistical significance.

Abbreviations: HBV, Hepatitis B virus; HCV, Hepatitis C virus; ASA, American Society of Anesthesiologists; TBIL, Total bilirubin; ALT, Alanine transaminase; PT, Prothrombin time; Plt, Platelet; AFP, Alpha-fetoprotein; ICG-R15, Indocyanine green retention test at 15 minutes.